Group 1 - The Hang Seng Medical Index ETF experienced a turnover of 8.47% during the trading session, with a transaction volume of 21.38 million yuan [3] - The ETF's scale increased by 18.48 million yuan over the past week, indicating significant growth [3] - The ETF's shares grew by 10 million shares this month, reflecting substantial growth [3] Group 2 - The current price-to-earnings ratio (PE-TTM) of the Hang Seng Medical Index ETF is 24.86, which is at a historical low, being in the 6.5% percentile over the past year [3] - A joint implementation plan for the digital transformation of the pharmaceutical industry has been issued by seven government departments, aiming for significant progress by 2027 [3] Group 3 - Short-term AI medical themes are expected to continue being a focus, with market attention shifting towards Q1 performance and potential improvements in the pharmaceutical industry by Q2 2025 [4] - The top ten weighted stocks in the Hang Seng Medical Index account for 57.69% of the index, including companies like BeiGene, WuXi Biologics, and JD Health [4] - Investors without stock accounts can access the Hang Seng Medical Index ETF through a linked fund for investment opportunities in the Hong Kong medical sector [4]

Core Viewpoint - Tsinghua University has established an Artificial Intelligence Hospital aimed at transforming the medical model through AI integration, enhancing healthcare efficiency, and addressing the shortage of general practitioners [1][2]. Group 1: Hospital Development - The construction of the AI hospital will be phased, initially relying on Tsinghua University’s AI capabilities and interdisciplinary medical engineering collaboration, with pilot programs in general medicine and specialized fields such as ophthalmology and radiology [1]. - The long-term goal is to operationalize the AI hospital, promoting a disruptive change in healthcare delivery [1][2]. Group 2: AI Integration in Healthcare - The AI hospital aims to break the traditional "hospital + AI" model by embedding AI functionalities into clinical services, assisting doctors in precise decision-making, improving service efficiency, and reducing operational costs [2]. - The hospital will serve as a key platform for medical education and training, fostering a new generation of "AI collaborative doctors" [2]. Group 3: Research and Innovation - Tsinghua University’s Intelligent Industry Research Institute emphasizes that AI is a critical engine of the Fourth Industrial Revolution, with smart healthcare being a significant area of research and application [3]. - The "Zijing AI Doctor" system, developed by Tsinghua's team, is set to enhance the evolution of AI doctors, laying a foundation for the AI hospital's construction [3]. - An academic clinical center has been launched to promote the integration and standardization of medical resources, focusing on collaborative development in medical education and research [3].

华为与中山七院共建"鲲鹏+昇腾"自主创新平台，将实现医院业务系统、数据库及ICT基础设施的智能 化。创新中心通过AI驱动影像质控优化、远程智能诊疗探索、智慧化病区管理升级及AI辅助临床决策 优化，打造覆盖诊疗全流程的智能化解决方案。 中山七院院长何裕隆强调，智慧医院是公立医院高质量发展的必由之路，此次合作是院企技术整合的典 范，期待通过共建创新中心，实现"优质资源全域共享"。 深圳商报•读创客户端记者 陈姝 4月23日，中山大学附属第七医院（以下简称"中山七院"）与华为技术有限公司（下文简称"华为"）签 署全面合作协议，并与联影医疗技术集团有限公司、深圳市联新移动医疗科技有限公司（以下简称"联 影""联新"）在深圳共同签署三方合作协议，合作共建"中山大学附属第七医院智慧医疗联合创新中 心"（以下简称"创新中心"）。 揭牌仪式（活动主办方供图） 创新中心将采用即将建成的10.0P级医疗人工智能算力中心，通过产学研医深度融合，推动智慧医疗自 主创新，促进医院高质量发展，助力国家实施"健康中国"战略。 在揭牌仪式上，中山七院副院长魏富鑫表示，此次的合作亮点是通过技术赋能，破解临床痛点。此次合 作以打造"三位一体"智 ...

本报讯 （记者李勇）4月25日，辽宁何氏眼科医院集团股份有限公司（以下简称"何氏眼科"）发布《2024年环境、社会和 公司治理（ESG）报告》，从多个维度全面展示过去一年公司在ESG领域的布局与实践成果，以及在打造"智慧光明城"，推动 可持续发展道路上的坚定决心与积极作为。 （编辑 张伟） 自创立以来，何氏眼科始终以科技创新为引领，秉持"奉献社会、百姓信赖、创新引领、共创幸福"的核心价值观和"科技 人文"的经营理念，坚持"预防为主、防治结合"的服务理念，依托创新技术和专业人才，为各类眼病患者提供眼科全方位诊疗 服务。公司在白内障、青光眼、玻璃体视网膜病变、干眼症、中医眼科、屈光不正等诊疗领域积累了丰富的临床经验和技术优 势。 报告显示，何氏眼科围绕"健康中国"战略方向和全球眼健康总体方向，以构建"智慧光明城"为战略目标，积极推进医疗健 康产业线上线下融合布局。依托独有的眼健康全产业链生态平台优势，借助大数据、人工智能、基因技术、干细胞技术等创新 手段，通过精准医疗和智慧医疗赋能，为患者提供数字化、全方位、全场景、全生命周期的眼健康管理服务新模式。公司坚持 以人为本，注重激发员工潜能与归属感，打造安全、公平、关 ...

在智慧城市领域，报告期内，公司参与智慧建筑领域顶层设计，完成团体标准《智慧建筑评价标准》编 制并颁布实施，彰显了公司在智慧城市建设中的顶层设计能力与复杂项目落地实力。 研发方面，2024年，公司投入研发费用3445.83万元。截至报告期末，子公司新申请29项软件著作权， 申报22项发明专利，新取得23项软件著作权证书和8项发明专利授权。延华医疗团队不断突破技术壁 垒，取得多项核心发明专利，如Web版藏文电子病历编辑器、多模态多接收方数据传输路由方法、动态 存储模式的主索引管理方法等，进一步形成技术竞争优势。 项目实践层面，公司持续深耕智能化咨询设计领域，以优质服务能力打造标杆项目，推进多个智能化咨 询设计项目。其中，签订中海成都天府新区超高层项目补充协议，进一步巩固在高端商业地产智慧化领 域的领先地位。此外，公司参与的《智慧街镇精准服务体系建设》项目荣获上海市质量技术进步奖。 在云平台领域，公司立足智慧建筑数字化升级需求，自主立项《智慧建筑AIoT平台》《智慧康养云平 台》等项目，开展需求市场调研并完成技术架构和功能设计。报告期内，完成了肥城数字乡村大数据平 台开发的初期工作，承担的普陀区数字化转型专项资金项 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000516 证券简称：国际医学 公告编号：2025-010 西安国际医学投资股份有限公司2024年年度报告摘要 一、重要提示 本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投资者 应当到证监会指定媒体仔细阅读年度报告全文。 所有董事均已出席了审议本报告的董事会会议。 非标准审计意见提示 □适用 √不适用 董事会审议的报告期利润分配预案或公积金转增股本预案 □适用 √不适用 公司计划不派发现金红利，不送红股，不以公积金转增股本。 董事会决议通过的本报告期优先股利润分配预案 1、公司简介 ■ 2、报告期主要业务或产品简介 （一）主要业务 公司以大健康医疗服务和现代医学技术转化应用为主业。目前，正在运营西安高新医院、西安国际医学 中心医院等综合性医疗机构。在医疗领域，公司探索并发展了"综合医疗+特色专科"创新业务模式，旨 在满足广大群众多元化医疗健康需求，充分发掘综合性医疗机构的协同效应。一方面致力于提供高质量 普惠型医疗服务，成功打造了脑科、心血管、消化、胸科、肿瘤、血液病、骨科等多个优势专科，开展 了一系列技术含 ...

Core Viewpoint - The company, Tianshan Electronics, has reported significant growth in revenue and net profit, driven by advancements in the automotive display sector and a focus on customized display solutions [12][13]. Company Overview - Tianshan Electronics specializes in the research, design, production, and sales of customized LCD displays and modules, positioning itself as a national high-tech enterprise with comprehensive supply capabilities [3][4]. - The company emphasizes a business philosophy centered on health, sustainability, and progress, aiming to provide personalized display solutions to industry-leading clients [3]. Financial Performance - For the reporting period, the company achieved operating revenue of 1,476.848 million yuan, a year-on-year increase of 16.54% - The net profit attributable to shareholders reached 150.3843 million yuan, up 39.99% year-on-year, with a significant increase in net profit growth rate compared to revenue growth [12]. - The net cash flow from operating activities was 121.6201 million yuan, reflecting an 82.08% increase [12]. Business Model - The company operates on an order-based production model, ensuring efficient procurement and production processes tailored to customer demands [6][7]. - Tianshan Electronics has established a stable supply chain with multiple suppliers for key materials, ensuring timely and reliable procurement [6]. Key Growth Drivers - The automotive electronics sector has shown significant growth, with the company expanding its product offerings to include advanced display technologies for various vehicle types [12][13]. - The company is investing in dual-base collaboration to enhance production capabilities and meet increasing market demands in automotive and smart home sectors [13][14]. Product Development and Innovation - Tianshan Electronics is focusing on high-value product development, including innovations in touch screen technology and advanced display modules [15][17]. - The company is actively developing new products such as smart serial display modules and variable light control rearview mirror modules, targeting growth in the automotive sector [16]. Strategic Initiatives - The company has implemented a dual mechanism of stock incentive plans and share buybacks to enhance governance and drive sustainable growth [18]. - Tianshan Electronics aims to deepen its presence in the professional display market by leveraging technological innovation and expanding its product matrix [19].

Core Insights - Artificial Intelligence (AI) is increasingly integrated into the medical field, assisting in various tasks from drug development to patient diagnosis and treatment [1][2][4][6][7][10][14] - The number of registered AI healthcare companies in China has rapidly increased, with over 764,000 companies established in recent years, indicating a growing interest and investment in AI healthcare solutions [21][24] AI Applications in Healthcare - AI is being utilized in lung nodule screening, significantly improving detection rates and efficiency for doctors, with sensitivity rates exceeding 90% for identifying nodules [2][4][6] - AI systems can quickly analyze CT scans, reducing the time required for doctors to review images and allowing for more accurate assessments of nodule risk [4][5][6] - The AI-assisted imaging systems have expanded to identify various conditions, including coronary artery disease and pulmonary embolism, showcasing their versatility [5][6] Precision Medicine - AI is enhancing precision medicine by predicting optimal drug dosages based on individual patient data, improving the success rate of treatments from 30% to over 60% [6][19] - AI systems are being developed to predict tumor infiltration ranges in liver cancer patients, achieving an accuracy rate of around 90% [6] Integration and Efficiency - Hospitals are increasingly adopting AI systems to streamline operations, such as patient record management and prescription verification, which can filter out over 90% of unreasonable prescriptions [11][12] - AI is being used to track patients who need follow-up visits, successfully identifying over 10,000 patients in a short period [13] Challenges and Future Directions - Despite the rapid development of AI in healthcare, challenges remain, including the need for regulatory frameworks, data sharing between institutions, and the integration of AI into existing workflows [22][23][24][25] - The healthcare industry is exploring how to effectively implement AI solutions to enhance overall efficiency and quality of care, particularly in underserved areas [14][19][20]

据介绍，"镜观"是全球首个深度融合大数据、AI技术与医疗资源的消化内镜全场景智能体，由复旦大学 附属中山医院等研发，通过整合超百万例内镜影像，构建消化内镜多模态基础模型，并依托国产自主 AI芯片实现医院端侧安全部署，形成"感知-决策-执行-进化"的完整智能链。 "镜观"可以成为患者的私人医疗顾问，除了一对一详细解读报告、答疑解惑之外，还可以通过知识图谱 及专病数据库，深入解读疾病相关情况，进一步实现预防科普和健康宣传等功能。它可以是医生的"手 术智囊伙伴"，医生可以通过"镜观"搭载的眼动和语音交互功能，在手术中实时获取病灶分析。同 时，"镜观"还能自动生成结构化报告，医生只需要查缺补漏和最终确认，文书时间可至少缩短至 50%。"镜观"还搭载了诊疗规范库，能智能预警操作风险，为基层医生提供三甲级水平的实时指导。 此外，"镜观"还是辅助医院管理决策的"科室大管家"，系统基于国产AI算力平台开发，通过"管理驾驶 舱"进行数据资源整合、智能分析，实现科室运转的精准调控。在安全性方面，做到了"数据不出院"的 安全架构，也使得"镜观"可在基层医院快速部署。据透露，未来三年，该平台计划接入全国300家医疗 机构，培训200 ...

Core Insights - Recently, Industrial Bank's Urumqi branch has established a deep cooperation with a leading regional pharmaceutical retail chain to launch a "Smart Pharmaceutical Settlement Service Solution" based on the bank's aggregated payment products [1][2] - The solution focuses on "one code aggregation" to address the fragmented payment issues in pharmaceutical retail, integrating various payment methods and enhancing operational efficiency and user value [1] Group 1: Partnership and Solution Overview - The collaboration aims to create a new paradigm for digital transformation in the pharmaceutical industry by integrating payment, data, and financial capabilities [1] - The solution supports multiple payment channels, including WeChat, Alipay, and Cloud Flash Payment, significantly improving settlement efficiency for clients [1] Group 2: Operational Efficiency and Data Management - The robust customer management platform addresses various challenges such as multi-store reconciliation, personnel management, and permission management, providing comprehensive data support for centralized operations [1] - The integration of customer sales management systems with payment channels enhances the cohesion of business and financial operations [1] Group 3: Broader Financial Services - To date, Industrial Bank's Urumqi branch has provided diverse financial services to multiple healthcare entities, including pharmaceutical companies, hospitals, and retail pharmacies, covering payment settlement, financing, account management, and wealth management [1] - The aggregated payment is evolving from a transaction tool to a digital foundation for the health industry, connecting health services through every payment [2]